The automated molecular diagnostic platform uses a blood sample for accurate detection of bacteria in the blood within three hours on a closed system.

The time saving is critical as mortality rates for patients with sepsis increase by about eight per cent for every hour of delay in diagnosis.

The technology is based on a dual-stage nucleic acid purification procedure designed to conduct multiplexed microbial detection for diagnosis.

Cell lysis, dual-stage DNA purification, multiplex PCR and endpoint detection are enclosed and fully contained within the SeptiCARD, enabling fully-automated detection and reduced risk of cross-contamination.

SeptiCARD is undergoing research and is yet to obtain FDA clearance for in vitro diagnostic use.